About Alanine--tRNA ligase, cytoplasmic
Alanine--tRNA ligase, cytoplasmic (AARS1) is a protein
from Homo sapiens identified by UniProt accession
P49588, 968 residues long.
MolForge cross-references it against 0 known binders and
233 disease associations.
Target properties
| Protein name | Alanine--tRNA ligase, cytoplasmic |
|---|
| UniProt accession | P49588 |
|---|
| Gene | AARS1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 968 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (233)
Diseases linked to this target (Open Targets).
- Charcot-Marie-Tooth disease axonal type 2N · score 0.73
- developmental and epileptic encephalopathy, 29 · score 0.71
- undetermined early-onset epileptic encephalopathy · score 0.63
- Autosomal dominant Charcot-Marie-Tooth disease type 2N · score 0.60
- trichothiodystrophy 8, nonphotosensitive · score 0.58
- Charcot-Marie-Tooth disease type 2 · score 0.55
- Charcot-Marie-Tooth disease · score 0.55
- developmental and epileptic encephalopathy · score 0.54
- genetic disorder · score 0.51
- leukoencephalopathy, hereditary diffuse, with spheroids 2 · score 0.51
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P49588-F1 | alphafold | PREDICTED | 90.42 | — |
Amino-acid sequence (968 residues)
MDSTLTASEI RQRFIDFFKR NEHTYVHSSA TIPLDDPTLL FANAGMNQFK PIFLNTIDPS HPMAKLSRAA NTQKCIRAGG KHNDLDDVGK DVYHHTFFEM LGSWSFGDYF KELACKMALE LLTQEFGIPI ERLYVTYFGG DEAAGLEADL ECKQIWQNLG LDDTKILPGN MKDNFWEMGD TGPCGPCSEI HYDRIGGRDA AHLVNQDDPN VLEIWNLVFI QYNREADGIL KPLPKKSIDT GMGLERLVSV LQNKMSNYDT DLFVPYFEAI QKGTGARPYT GKVGAEDADG IDMAYRVLAD HARTITVALA DGGRPDNTGR GYVLRRILRR AVRYAHEKLN ASRGFFATLV DVVVQSLGDA FPELKKDPDM VKDIINEEEV QFLKTLSRGR RILDRKIQSL GDSKTIPGDT AWLLYDTYGF PVDLTGLIAE EKGLVVDMDG FEEERKLAQL KSQGKGAGGE DLIMLDIYAI EELRARGLEV TDDSPKYNYH LDSSGSYVFE NTVATVMALR REKMFVEEVS TGQECGVVLD KTCFYAEQGG QIYDEGYLVK VDDSSEDKTE FTVKNAQVRG GYVLHIGTIY GDLKVGDQVW LFIDEPRRRP IMSNHTATHI LNFALRSVLG EADQKGSLVA PDRLRFDFTA KGAMSTQQIK KAEEIANEMI EAAKAVYTQD CPLAAAKAIQ GLRAVFDETY PDPVRVVSIG VPVSELLDDP SGPAGSLTSV EFCGGTHLRN SSHAGAFVIV TEEAIAKGIR RIVAVTGAEA QKALRKAESL KKCLSVMEAK VKAQTAPNKD VQREIADLGE ALATAVIPQW QKDELRETLK SLKKVMDDLD RASKADVQKR VLEKTKQFID SNPNQPLVIL EMESGASAKA LNEALKLFKM HSPQTSAMLF TVDNEAGKIT CLCQVPQNAA NRGLKASEWV QQVSGLMDGK GGGKDVSAQA TGKNVGCLQE ALQLATSFAQ LRLGDVKN
Explore Alanine--tRNA ligase, cytoplasmic with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets